US 9,809,638 B2
Variant activin receptor
Jeonghoon Sun, Thousand Oaks, CA (US); Lei-Ting Tony Tam, Thousand Oaks, CA (US); Hui-Quan Han, Thousand Oaks, CA (US); Keith Soo-Nyung Kwak, Thousand Oaks, CA (US); and Xiaolan Zhou, Thousand Oaks, CA (US)
Assigned to Amgen Inc., Thousand Oaks, CA (US)
Filed by Amgen Inc., Thousand Oaks, CA (US)
Filed on Jun. 2, 2016, as Appl. No. 15/171,944.
Application 15/171,944 is a division of application No. 14/204,460, filed on Mar. 11, 2014, granted, now 9,447,165.
Application 13/080,515 is a division of application No. 12/074,877, filed on Mar. 5, 2008, granted, now 7,947,646, issued on May 24, 2011.
Application 14/204,460 is a continuation of application No. 13/080,515, filed on Apr. 5, 2011, granted, now 8,716,459, issued on May 6, 2014.
Claims priority of provisional application 61/065,474, filed on Feb. 11, 2008.
Claims priority of provisional application 60/905,459, filed on Mar. 6, 2007.
Prior Publication US 2016/0264644 A1, Sep. 15, 2016
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/00 (2006.01); C07K 14/71 (2006.01)
CPC C07K 14/71 (2013.01) [A61K 38/00 (2013.01); C07K 2319/00 (2013.01); C07K 2319/30 (2013.01)] 20 Claims
 
1. An isolated protein comprising a variant activin IIB receptor (vActRIIB) polypeptide wherein the polypeptide is selected from the group consisting of:
(a) a polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 18, wherein the polypeptide comprises an amino acid substitution at position 28, wherein the substitution at position 28 is A, W, Y, F, Q, V, I, L, M, K, or H for E;
(b) a polypeptide comprising the amino acid sequence set forth in amino acids 19 through 134 of SEQ ID NO: 18, wherein the polypeptide comprises an amino acid substitution at position 28, wherein the substitution at position 28 is A, W, Y, F, Q, V, I, L, M, K, or H for E;
(c) a polypeptide comprising the amino acid sequence set forth in amino acids 23 through 134 of SEQ ID NO: 18, wherein the polypeptide comprises an amino acid substitution at position 28, wherein the substitution at position 28 is A, W, Y, F, Q, V, I, L, M, K, or H for E;
(d) a polypeptide comprising the amino acid sequence set forth in amino acids 25 through 134 of SEQ ID NO: 18, wherein the polypeptide comprises an amino acid substitution at position 28, wherein the substitution at position 28 is A, W, Y, F, Q, V, I, L, M, K, or H for E; and
(e) a polypeptide having at least 99% identity to any one of (a) through (d), wherein the polypeptide comprises an amino acid substitution at the position corresponding to position 28 of SEQ ID NO:18, wherein the substitution at position 28 is A, W, Y, F, Q, V, I, L, M, K, or H for E, and wherein the polypeptide is capable of binding myostatin, activin A, or GDF-11.